Heather L. Mason Acquires 75,000 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) Stock

Assertio Holdings, Inc. (NASDAQ:ASRT) Director Heather L. Mason purchased 75,000 shares of the stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $60,000.00. Following the acquisition, the director now directly owns 287,650 shares in the company, valued at approximately $230,120. This trade represents a 35.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Assertio Trading Up 2.5 %

Shares of NASDAQ ASRT traded up $0.02 during mid-day trading on Tuesday, hitting $0.86. 72,581 shares of the stock were exchanged, compared to its average volume of 924,621. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01. Assertio Holdings, Inc. has a twelve month low of $0.73 and a twelve month high of $1.80. The stock’s fifty day simple moving average is $1.11 and its two-hundred day simple moving average is $1.18.

Assertio (NASDAQ:ASRT) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. The business had revenue of $29.20 million during the quarter, compared to the consensus estimate of $29.29 million. Assertio had a positive return on equity of 3.79% and a negative net margin of 54.46%. During the same quarter in the prior year, the company posted ($0.01) earnings per share. As a group, equities research analysts forecast that Assertio Holdings, Inc. will post -0.17 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Maxim Group began coverage on shares of Assertio in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 target price on the stock. StockNews.com upgraded Assertio from a “hold” rating to a “buy” rating in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Assertio

Hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors acquired a new position in shares of Assertio in the 3rd quarter valued at $26,000. Point72 DIFC Ltd bought a new stake in shares of Assertio in the second quarter worth about $40,000. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Assertio by 304.0% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 50,500 shares of the company’s stock valued at $60,000 after purchasing an additional 38,000 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Assertio in the 2nd quarter valued at approximately $70,000. Finally, Los Angeles Capital Management LLC bought a new stake in Assertio during the 2nd quarter worth approximately $77,000. 48.96% of the stock is currently owned by institutional investors and hedge funds.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.